Covaxin Maker Gets $19 Million For Development Of 'Variant Proof' Vaccine

Null

New Delhi: The Coalition for Epidemic Preparedness Innovations (CEPI) on Tuesday said it will provide up to USD 19.3 million (about Rs 149 crore) to Bharat Biotech International, the University of Sydney, and Switzerland-based ExcellGene SA for the development of a "variant-proof" SARS-CoV-2 vaccine candidate.  CEPI will fund the initiative under its USD 200 million programme to advance the dev...

Read Complete Article

Post a Comment

Previous Post Next Post